Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation

Area of Science:

• Cellular immunotherapy
• Regenerative medicine
• Genetic engineering

Background:

• Conventional T cell therapies face manufacturing limitations.
• Induced pluripotent stem cells (iPSCs) provide an expandable source for therapeutic T cells.
• iPSCs allow for genetic modification to enhance safety and efficacy, such as introducing chimeric antigen receptors (CARs).

Purpose of the Study:

• To review advancements in generating functional engineered T cells from iPSCs.
• To assess the progress towards clinical applicability of iPSC-derived T cells.
• To emphasize the importance of Good Manufacturing Practice (GMP) compliance in production.

Main Methods:

• Review of recent literature on iPSC differentiation and genetic engineering protocols.
• Analysis of methods for achieving hypo-immunogenicity and specific therapeutic functions.
• Evaluation of scalability, safety, and quality control measures for clinical translation.

Main Results:

• Significant progress has been made in generating engineered T cells from iPSCs over the last decade.
• Development of protocols aligning with GMP standards is crucial for clinical implementation.
• Genetic engineering of iPSCs enables the creation of standardized, rigorously assessed cell lines.

Conclusions:

• iPSC-derived T cells represent a promising, standardized, and scalable source for adoptive cell therapies.
• This approach offers potential for safer and more widely applicable engineered T cell products.
• The focus on iPSCs heralds a new era in T cell therapy, expanding treatment hope for more patients.